AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.70 | 38.30 | 0.45% |
| CAC 40 | 7,910.49 | 31.93 | -0.40% |
| DAX 40 | 24,122.40 | 86.29 | 0.36% |
| Dow JONES (US) | 41,877.81 | 799.43 | -1.87% |
| FTSE 100 | 8,786.46 | 5.34 | 0.06% |
| HKSE | 23,827.78 | 146.30 | 0.62% |
| NASDAQ | 18,888.37 | 254.35 | -1.33% |
| Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
| NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
| S&P 500 | 5,848.30 | 92.16 | -1.55% |
| S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
| SSE Composite Index | 3,387.57 | 7.10 | 0.21% |